SEVEN FLEET CAPITAL MANAGEMENT LP
Q2 2026 Form 13-F
MOUNTAIN VIEW, DELAWARE
CIK 0002092021
· CRD 335203
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2025
$605.9M Reported Value Total
SEVEN FLEET CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $434,581,362, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $434.6M gross asset value
Hedge Fund: $263.1M · Other: $171.4M
Source: Form ADV filed 2026-07-06
Reported value
$605.9M
Quarter over quarter
+26.1%
Holdings
96
Top-10 concentration
65.1%
Filing Structure
Reports holdings for
- DV Trading LLC · File #028-26555 · since Q4 2025 · declared by one filing
Key People
Form ADV owners & control persons
Brian Guan-Chyun Liu
MANAGING MEMBER
Rod Seung-Hwan Lim
LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 15, 2026 |
| Form | 13F-HR |
| Reported value | $605.9M |
| Positions | 96 |
| Change in reported value | +90.4% |
| New positions | 24 |
| Exited positions | 43 |
| Position turnover | 48.2% |
| Top-10 concentration | 65.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 15, 2026
|
96 | $605.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
115 | $318.3M |
|
Q4 2025 13F
Filed Feb 26, 2026
|
85 | $147.8M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $134.0M | 22.12% |
| 2 | TNGX TANGO THERAPEUTICS INC | $95.7M | 15.79% |
| 3 | RVMD REVOLUTION MEDICINES INC | $45.3M | 7.48% |
| 4 | PHVS PHARVARIS N V | $26.8M | 4.42% |
| 5 | LQDA LIQUIDIA CORPORATION | $20.5M | 3.38% |
| 6 | ELVN ENLIVEN THERAPEUTICS INC | $18.5M | 3.06% |
| 7 | ABVX ABIVAX SA | $14.8M | 2.45% |
| 8 | AVTX AVALO THERAPEUTICS INC | $14.2M | 2.35% |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | $12.9M | 2.13% |
| 10 | ASMB ASSEMBLY BIOSCIENCES INC | $11.9M | 1.96% |
| 11 | IPSC CENTURY THERAPEUTICS INC | $10.7M | 1.76% |
| 12 | CYTK CYTOKINETICS INC | $10.1M | 1.66% |
| 13 | TSHA TAYSHA GENE THERAPIES INC | $9.9M | 1.64% |
| 14 | MANE VERADERMICS INC | $9.8M | 1.62% |
| 15 | AVBP ARRIVENT BIOPHARMA INC | $8.6M | 1.41% |
| 16 | TARS TARSUS PHARMACEUTICALS INC | $7.9M | 1.31% |
| 17 | XNCR XENCOR INC | $7.8M | 1.29% |
| 18 | ROIV ROIVANT SCIENCES LTD | $7.8M | 1.29% |
| 19 | GLTO DAMORA THERAPEUTICS INC | $7.4M | 1.22% |
| 20 | AXSM AXSOME THERAPEUTICS INC | $7.1M | 1.16% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.